Subscribe to NRx Newsletter

Pipeline

Bringing Hope to Life through our NMDA Platform

We focus on serious, life-threatening conditions with major unmet medical needs. Our growing pipeline is powered by our proprietary, dual-targeted mechanism of action, which safely modulates the NMDA and 5HT2A receptors.

As we unlock our discoveries about the role of NMDA receptors throughout the human body, we leverage that research to bring hope to people with:

  • Depression
  • Suicidality
  • Chronic Pain
  • PTSD

Learn more about NMDA and 5HT2A Receptors >

Therapeutic Areas by Population Size in United States

Sources:

  1. National Institute of Mental Health,  https://www.nimh.nih.gov/health/statistics/bipolar-disorder
  2. US Dept of Veteran Affairs, https://www.ptsd.va.gov/understand/common/common_adults.asp
  3. Centers for Disease Control and Prevention, https://www.cdc.gov/mmwr/volumes/72/wr/mm7215a1.htm

BIPOLAR DEPRESSION & SUICIDAL IDEATION

Indication
Preclinical
Phase 1
Phase 2
Phase 3
Severe Bipolar Depression with Recently Suicidal Patients post stabilization

NRX-100™ (IV Ketamine)

Phase 3
*Collaboration Agreement with Study Leadership of two well-powered, academic clinical trials
NDA Filing H1 2024 | PDUFA est. 2024
Treatment of Suicidal Treatment-Resistant Bipolar Depression

NRX-101™

Phase 3
Enrollment Completed, Phase 2b/3 – Partnered w/ Alvogen Inc. & Lotus Pharma

CHRONIC PAIN WITH DEPRESSION

Indication
Preclinical
Phase 1
Phase 2
Phase 3
Chronic Back Pain

D-Cycloserine (DCS)

Phase 3
200 person, independent trial funded by DOD
Pending Data Readout
Chronic Nociceptive Pain

NRX-101™

Phase 2
IND Approved | Applied to NIH EPICNET & HEAL

POST TRAUMATIC STRESS DISORDER (PTSD)

Indication
Preclinical
Phase 1
Phase 2
Phase 3
PTSD in patients with Depression & Suicidality

NRX-101™

Phase 2
Nonclinical Evidence | Clinical Planning

COMPLICATED UTI

Indication
Preclinical
Phase 1
Phase 2
Phase 3
Complicated UTI incl. Pyelonephritis

NRX-101™

Phase 2
In Vitro Data | QIDP and Fast Track granted